Eli Lilly and Company (NYSE:LLY) Stock Sold Off Rep. Michael A. Rulli

Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on August 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on July 1st. The trade occurred in the Representative’s “MERRILL LYNCH MANAGED ACCOUNT” account.

Representative Michael A. Rulli also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 8/6/2026.
• Purchased $1,001 – $15,000 in shares of KLA (NASDAQ:KLAC) on 7/1/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/29/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 6/25/2026.

Eli Lilly and Company Trading Up 3.7%

Shares of NYSE LLY opened at $1,230.00 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business has a fifty day simple moving average of $1,162.38 and a two-hundred day simple moving average of $1,048.95. The firm has a market cap of $1.16 trillion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $625.90 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts expect that Eli Lilly and Company will post 36.77 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research report on Friday. Finally, Rothschild & Co Redburn lifted their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. This is the pill’s first approval outside the United States and opens access to a large European market. Foundayo will initially be sold privately by prescription; potential National Health Service coverage depends on a cost-effectiveness review. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: The authorization strengthens Lilly’s competitive position against Novo Nordisk in the fast-growing obesity-treatment market. Investors are evaluating whether a convenient oral GLP-1 option can broaden patient adoption beyond injectable therapies. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Analysts raised Lilly’s estimated fair value to $1,297.31 from $1,270.37, citing momentum in Mounjaro, Zepbound, retatrutide and Foundayo. The revisions reinforce expectations for continued GLP-1-driven growth. Eli Lilly Fair Value Bump
• Positive Sentiment: Lilly’s latest quarter delivered revenue of approximately $22.97 billion, up 47.7% year over year, and EPS of $8.38 versus the $6.40 consensus estimate. Fiscal 2026 EPS guidance of $35.50 to $36.50 signals management’s confidence in demand. Eli Lilly Posts Blowout Growth
• Neutral Sentiment: Possible U.S. policies encouraging domestic drug manufacturing could benefit Lilly if its production footprint is viewed favorably, but compliance costs and final policy requirements remain uncertain. Lilly and Novo Nordisk Manufacturing Policies
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for about $5.95 million, reducing her holdings by 29.63%. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, it is a limited signal regarding Lilly’s business outlook. SEC Form 4 Filing

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently made changes to their positions in the stock. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Maseco LLP boosted its position in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. increased its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. raised its position in Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after buying an additional 27 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Representative Rulli

Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio’s 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027.

Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio’s 6th Congressional District. He declared candidacy for the 2026 election.

Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli’s career experience includes working as the director of operations with Rulli Bros. Markets.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.